A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)

Inclusion Criteria:

• Have Lipoprotein(a) [Lp(a)] ≥175 nanomoles per liter (nmol/L).

• Meet criteria of either 2a or 2b:

2a: Individuals 18 years of age or older with established atheroscleroticcardiovascular disease (ASCVD) with an event or revascularization.

2b: Individuals 55 years of age or older who are at risk for a first cardiovascular (CV) event and either: Documented coronary artery disease (CAD), carotid stenosis,or peripheral artery disease (PAD) without history of event or revascularization;known familial hypercholesteremia; or a combination of high-risk factors.

Exclusion Criteria:

• Have had a major cardiovascular event or surgery, such as myocardial infarction (MI), stroke or coronary or peripheral revascularization, < 60 days before screening

• Have uncontrolled hypertension

• Have New York Heart Association class IV heart failure.

• Have lipoprotein apheresis within 90 days of screening, or planned lipoproteinapheresis during the study.

• Have severe renal failure, defined as

• Estimated glomerular rate (eGFR) <15 milliliters per minute per 1.73 meterssquared (mL/min/1.73m2) at screening Visit 1, or ongoing dialysis.

• Have a diagnosis of active nephrotic syndrome, or urine albumin-creatinine ratio (UACR) of ≥5000 mg/g at screening Visit 1.

• Have acute or chronic hepatitis, known cirrhosis, signs and symptoms of any otherliver disease other than metabolic-associated steatotic liver disease, orexclusionary laboratory results as determined by the central laboratory duringscreening.